LDE Stock Chart & Stats
€3.76
€0.04(1.08%)
At close: 4:00 PM EDT
€3.76
€0.04(1.08%)
Day’s Range― - ―
52-Week Range€3.12 - €7.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€143.76M
Enterprise Value€386.59
Total Cash (Recent Filing)€17.47M
Total Debt (Recent Filing)€142.61M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 12, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding37,509,407
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)-19.16
Price to Sales (P/S)2.10
P/FCF Ratio43.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.42Price Target Upside44.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.92
Revenue Forecast (FY)€105.39M
Bulls Say, Bears Say
Bulls Say
CDMO Service-based ModelLifecore’s core CDMO model—development, fill-finish and related services—creates fee-for-service revenue tied to customer programs. This business mix fosters recurring contracted work and technical specialization, supporting steadier revenue streams and long-term customer relationships.
2026 Cash Flow TurnaroundA meaningful shift to positive operating and free cash flow in 2026 improves near-term liquidity and reduces reliance on external funding. Sustained cash generation can fund working capital or selective investments and lowers refinancing pressure from elevated leverage if the trend persists.
Steady Gross MarginsRelatively stable gross margins indicate consistent unit economics in core manufacturing activities despite revenue swings. Margin stability provides a foundation for operating leverage: higher utilization or better mix could translate to structural profit improvement without needing margin expansion.
Bears Say
Stressed Balance SheetElevated leverage and negative equity materially constrain financial flexibility and raise refinancing and solvency risk. This capital-structure weakness limits the company's ability to fund growth, absorb shocks, or negotiate favorable financing until equity or deleveraging improves.
Ongoing Operating LossesPersistent operating and large net losses erode retained capital and make sustainable profitability a prerequisite for long-term viability. Continued losses increase dependence on debt or equity raises, exacerbating dilution or leverage risk and hindering strategic investments.
Flat And Volatile RevenueLack of consistent top-line growth and historical revenue volatility limit scale benefits and make long-term planning difficult. Flat revenue hampers the company’s ability to leverage fixed costs and convert stable gross margins into reliable operating profits over time.
Lifecore Biomedical News
LDE FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was €3.12 and its highest was €7.30 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is €143.76M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is May 12, 2027 which is in 278 days.
How were Lifecore Biomedical’s earnings last quarter?
Currently, no data Available
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Undervalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,509,407 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in DE:LDE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Company Description
Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LDE Company Deck
LDE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.View all DE:LDE earnings summariesLDE Stock 12 Month Forecast
Average Price Target
€5.42
▲(44.26% Upside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―